Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs
Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.
Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.
What's Your Reaction?
